International Clinical Trial: A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808515) titled 'A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)' on Sept. 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Regeneron Pharmaceuticals

Condition: Locally Advanced Basal Cell Carcinoma

Intervention: Drug: Cemiplimab Drug: Vidutolimod

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 15, 2026

Target Sample Size: 135

To know more, visit https://clinicaltrials.gov/study/...